Skip to main content
Equibles
EW logo

EW · Edwards Lifesciences Corp · Metrics

Track EW — free

Use EW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$86.32 -1.76 (-2.00%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$49.74B
Shares
576.40M
Volume · Sep 30 4.89M Avg daily vol (3M) 3.86M

EW metrics

81 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$88.08
Market cap
$49.74B

Price action

20 metrics
Price change (1W)
-0.8%
Price change (30D)
-2.9%
Price change (3M)
-2.6%
Price change (6M)
+10.0%
Price change (YTD)
+3.3%
Price change (1Y)
+14.1%
Trailing year
Price change (5Y)
-22.4%
52-week high
$95.18
52-week low
$72.65
Change from 52-week high
-7.5%
Change from 52-week low
+21.2%
Annualized volatility
25.3%
Annualized volatility (3M)
23.7%
Beta
0.6
RSI (14D)
50.3
Price vs SMA 50
-0.4%
Price vs SMA 200
+3.5%
Avg volume (3M)
3.86M
Relative volume
0.9
Average dollar volume
$341.28M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
576.40M

Valuation

12 metrics
P / E (TTM)
50.6
Trailing earnings · reciprocal yield 2.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
7.6×
reciprocal yield 13.1%
P / book
4.7
reciprocal yield 21.3%
FCF yield
2.9%
TTM · current market cap
Buyback yield
2.4%
P / FCF
34.7
reciprocal yield 2.9%
P / operating cash flow
28.9
reciprocal yield 3.5%
Earnings yield
2.0%

Historical valuation

8 metrics
P / E historical average (3Y)
28.0×
reciprocal yield 3.6%
P / E historical average (5Y)
33.1×
reciprocal yield 3.0%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
2.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-23

Profitability

9 metrics
Gross margin
77.8%
Operating margin
22.3%
Trailing 12 months
Net margin
15.5%
Gross profit (TTM)
$5.07B
Operating profit (TTM)
$1.45B
Net income (TTM)
$1.01B
Trailing 12 months
Diluted EPS (TTM)
$1.74
FCF margin
22.0%
Effective tax rate
31.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$17.80

Growth

11 metrics
Revenue growth YoY
+13.6%
Year over year
Net income growth YoY
-27.4%
Revenue (TTM)
$6.51B
Trailing 12 months
EPS growth YoY
-25.0%
Shares change YoY
-1.8%
Year over year · fewer shares
Revenue CAGR (3Y)
+10.8%
Revenue CAGR (5Y)
+6.7%
EPS CAGR (3Y)
-9.1%
EPS CAGR (5Y)
+7.1%
FCF CAGR (3Y)
+11.1%
FCF CAGR (5Y)
+15.6%

Quality

14 metrics
Return on equity
9.5%
Return on assets
7.3%
Debt / equity
—
Current ratio
4.5
EBITDA (TTM)
$1.61B
Free cash flow (TTM)
$1.43B
Quick ratio
3.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.91B
Total assets
$13.87B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.72B
Capital expenditures (TTM)
$286.70M
R&D (TTM)
$1.09B
SG&A (TTM)
$2.20B
Stock compensation (TTM)
$168.00M
R&D / revenue
16.7%
Stock compensation / revenue
2.6%

Ownership (13F)

3 metrics
13F filers
1,343
13F filer change QoQ
+44
Institutional ownership
91.1%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
47 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.54M
Insider-sentiment score
22 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1099800 CUSIP 28176E108 13F (30d) 34 filings 21 filers Visit website Investor relations